ArticleKidney international reports2025
Development and Validation of Multiplex Assays for Lupus Nephritis Activity Biomarkers.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Introduction: We aimed to develop multiplex (MLP) assays of 6 biomarkers, namely adiponectin, neutrophil gelatinase-associated lipocalin (NGAL), monocyte chemoattractant protein-1 (MCP-1), kidney injury molecule-1 (KIM-1), ceruloplasmin, and hemopexin used in the Renal Activity Index for Lupus (RAIL) and establish MLP assays using the Milliplex MLP and the electrochemiluminescence Mesoscale Discovery (MSD) technology, to compare with the gold standard of established single immunoassays. Methods: A total of 104 banked urine samples from the CCHMC Lupus Cohort were used. RAIL biomarker concentrations were assayed using established individual immunoassays, and concentrations were compared with MLP reagents using both the MSD and MLP platforms. MLP assay development involved assessment of biomarker concentrations in 40 individual urine samples, followed by evaluation of optimal sample dilution using 14 additional samples on each platform. Then 50 samples were assayed in duplicate under optimized MLP conditions, and biomarker concentration compared with those using single assays. After correcting for urine creatinine, RAIL scores of the samples were determined and compared between testing platforms (single immunoassays, MLP). Results: Our results indicate that a 1:25 urine dilution was optimal when using the MLP platforms. Biomarker concentrations by single immunoassays correlated with those on the Milliplex platform strongly for KIM-1, MCP-1, and NGAL ( Conclusion: Milliplex technology is suitable to measure RAIL biomarker concentrations in urine samples diluted 1:25.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.